Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 178

Targeting Aquaporin 1 to treat edema in brain tumor

Brain edema is a major cause of death for brain cancer. Edema surrounding the tumor results from disruption of the blood-brain barrier (BBB), allowing leakage of excess fluid across the blood vessel wall, which leads to swelling brain tissues and a rapid increase in pressure within the skull. Although the ...

Testing cytotoxic effects and deciphering signalling pathways engaged by a ...

Glioblastoma (GBM) is the most common malignant brain tumor, being highly invasive and not responsive to standard treatment (surgery, radiotherapy, and chemotherapy). Moreover, a major determinant of the high lethality of GBM is the presence of self-renewing, tumorigenic glioblastoma stem-like cells (GSCs) that threateningly support the development and the progressive ...

MiR181 as novel biomarkers in precision medicine of Bile Duct ...

Bile Tract Cancers (BTC) include cholangiocarcinoma (CCA) and gallbladder cancer (GBC) and their incidence is increasing worldwide [1, 2] . Lack of effective radical treatments highlights the need for a better understanding of BTC biology and mechanisms of response to treatment [1, 2]. Eighty-percent of BTC patients present at an advanced stage, when treatment options ...

Elucidation of regional differences of ONC201 Response in H3K27...

Diffuse intrinsic pontine glioma (DIPG), recently renamed diffuse midline glioma (DMG), is an extremely aggressive and lethal pediatric brain tumor with no proven therapies beyond standard radiation. As such, few children with this diagnosis survive beyond 2 years, highlighting the dire need to identify and investigate novel genetic therapeutic targets in ...

Unlocking the translational potential of the DIPG epigenome for a ...

Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric brain tumor with a very poor outlook, with an expected survival of one year. Lack of access to biological tissue sample continues to be the largest barrier to advancing treatment. In 2016, the World Health Organization (WHO) reclassified DIPG tumors as diffuse ...